Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6075652 | 0.91 | CES2 (0.45) | ACP3TSHRALDH1A1KIF11TRPV6 | |
| SCHEMBL14034033 | 0.83 | IDO1 (0.54) | ACP3TSHRALDH1A1CACNA1CTACR1 | |
| SCHEMBL4152500 | 0.82 | IDO1 (0.56) | ACP3TSHRALDH1A1OPRM1OPRD1 | |
| SCHEMBL11820501 | 0.81 | TSHR (0.61) | TSHRALDH1A1RAB9AIDO1TDO2 | |
| SCHEMBL28495393 | 0.80 | TSHR (0.56) | ACP3TSHRALDH1A1KIF11TRPV6 | |
| SCHEMBL17071860 | 0.78 | ACP3 (0.55) | ACP3TSHRALDH1A1KIF11TRPV6 | |
| SCHEMBL477694 | 0.78 | ACP3 (0.59) | ACP3TSHRALDH1A1KIF11TRPV6 | |
| SCHEMBL477425 | 0.78 | ACP3 (0.59) | ACP3TSHRALDH1A1KIF11TRPV6 | |
| SCHEMBL2010847 | 0.78 | ACP3 (0.55) | ACP3TSHRALDH1A1KIF11TRPV6 | |
| SCHEMBL7523008 | 0.78 | ACP3 (0.55) | ACP3TSHRALDH1A1KIF11TRPV6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| WO-2019104011-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| US-9663476-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2947067-A1 | Glycine transporter-1 inhibitors | Amgen, Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-8735383-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2041088-B1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| CN-101479243-B | Glycine transporter-1 inhibitors | AMGEN INC | 2013-01-02 | — | — | CN | disclosed |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2012-08-02 | — | — | US | disclosed |
| CN-101479243-A | Glycine transporter-1 inhibitors | AMGEN INC (US) | 2009-07-08 | — | — | CN | disclosed |
| US-7538114-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-2041088-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| US-7476681-B2 | anticarcinogenic agent; prostate cancer, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, hirsutism, acne, androgenic alopecia, or polycystic ovary syndrome, prostate, lung, pancreatic, colon, renal cancer, myeloid leukemia | SCHERING CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476681-B2 | anticarcinogenic agent; prostate cancer, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, hirsutism, acne, androgenic alopecia, or polycystic ovary syndrome, prostate, lung, pancreatic, colon, renal cancer, myeloid leukemia | SCHERING CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2008002583-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | disclosed |
| EP-1423381-B1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORP (US) | 2007-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | ACP3 4537/4885TSHR 3602/4885ALDH1A1 1282/4885 |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | SLC18A2, SLC7A11, SLC6A5 | ACP3 4339/4885TSHR 3581/4885ALDH1A1 1305/4885 |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | ACP3 4339/4885TSHR 3581/4885ALDH1A1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.